FDA & Government News

June 18, 2026

Top 10 FDA Recalls Physicians Should Know

A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.

Conexiant

June 15, 2026

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Conexiant

June 08, 2026

FDA Expands Marstacimab Indication in Hemophilia A and B

Phase 3 BASIS and BASIS KIDS data supported the expanded indication across pediatric and inhibitor-pretreated populations.

Conexiant

May 21, 2026

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Conexiant

May 04, 2026

Food Fight Brewing in Hospitals

New federal diet push collides with clinical realities, as doctors weigh patient needs against policy signals.

Kff Health News

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

March 26, 2026

St. Louis Pediatrician Gets 20-Year Sentence

A physician exploited patients with addiction for nearly a decade, trading prescriptions for sex acts, photos, and cash

Conexiant

March 18, 2026

Exercise in a Pill Is Now in Human Trials

Atrogi's ATR-258 just dosed its first subjects — and the muscle data it's hunting could reframe how we treat weight loss.

Conexiant

March 17, 2026

Obesity Medications Get New Guidance

Panel outlines pharmacotherapy roles across obesity complications and long-term weight management.

Conexiant

March 02, 2026

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

Conexiant

February 12, 2026

FDA Approves HRT Label Changes

The agency cited updated evidence in revising hormone therapy safety language.

Conexiant

Self-Management May Reduce Chronic Low Back Pain

FDA & Government News

Top 10 FDA Recalls Physicians Should Know

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

FDA Expands Marstacimab Indication in Hemophilia A and B

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Food Fight Brewing in Hospitals

Daily News

St. Louis Pediatrician Gets 20-Year Sentence

Exercise in a Pill Is Now in Human Trials

Obesity Medications Get New Guidance

FDA Okays Weekly Option in Achondroplasia

FDA Approves HRT Label Changes

Recommendations

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Trending Now

Self-Management May Reduce Chronic Low Back Pain

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dentistry

ADA News

CDE World

New Dentist News

Conexiant

AACE Endocrinology AI

Conexiant

GI & Hepatology News

The ASCO Post

JADPRO

JNCCN

JNCCN 360

ASCO AI in Oncology

Glaucoma Physician

Ophthalmology Management

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

The Pathologist

FDA & Government News

Daily News

Recommendations